Cover Story
By Matthew Bin Han Ong
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- Trump 2016: A look back at the 45th president’s impact on oncology
- Art exhibit at University of Miami Sylvester bridges North and South America
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024